DUAL
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 1/2. fázis
Where in Hollandia
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, HollandiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Trial code
- EU 2023-505453-40-00
- Record updated
- 2025. július 11.
- Original description
To confirm lesion-specific uptake of 99mTc-hPSMA by PCaRead full original descriptionShow less
99mTechnetium and Cyanine-5 (HybriD) Prostate Specific Membrane Antigen (PSMA) Tracer-gUided Surgery in ProstAte Cancer - a FeasibiLity Study (DUAL study)
To confirm lesion-specific uptake of 99mTc-hPSMA by PCa
Inclusion: Male, aged 18 years and older; Histopathologically confirmed adenocarcinoma of the prostate; Had a routine PSMA PET/CT within 90 days before surgery; PSMA avid tumor on PSMA PET/CT; Suitable for RALP +ePLND, as per institutional guidelines (no minimum or maximum lesions on PSMA PET); Written and signed informed consent.
Exclusion: Previous radiotherapy of the abdomen; Ongoing androgen deprivation therapy (ADT) or within 6 months prior to surgery; Previous or ongoing chemotherapy; Previous or ongoing immunotherapy; History of other malignancy within 5 years prior to surgery (except skin malignancies); History of clinically significant allergies including anaphylaxis; History of impaired renal function (defined as eGFR<60ml/min/1,73m2); Severe claustrophobia interfering with PET/CT or SPECT/CT scanning.